Lyra Therapeutics gains amid new data on nasal disease treatment
29/04/2022 17:08
** Shares of drug developer LYRA.O rise 3.9% to $5.56
** LYRA reports new data from mid-stage study testing its
experimental therapy, LYR-210, in adult patients with chronic
rhinosinusitis - a condition causing inflammation in spaces in
the nose and head urn:newsml:reuters.com:*:nPn6dhD3a
** Patients treated with high dose of therapy reported
decreased rhinologic (nose), ear/facial and sleep dysfunction,
among other symptoms- LYRA
** LYR-210 is designed as an alternative to sinus surgery
for patients whose illness persists despite treatment
** Stock up 27.5% YTD
(Reporting by Amruta Khandekar)
((Amruta.Khandekar@thomsonreuters.com;))